Childhood physical, environmental, and genetic predictors of adult hypertension: the car- diovascular risk in young Finns study. Circulation. 2012;126:402 9. S5.3-3. Parkinson JRC, Hyde MJ, Gale C, et al. Preterm birth and the meta- bolic syndrome in adult life: a systematic review and meta-analysis. Pediatrics. 2013;131:e1240 63. S5.3-4. de Jong F, Monuteaux MC, van Elburg RM, et al. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension. 2012;59:226 34. 5.4. Secondary Forms of Hypertension S5.4-1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403 19. S5.4-2. Selassie A, Wagner CS, Laken ML, et al. Progression is acceler- ated from prehypertension to hypertension in blacks. Hypertension. 2011;58:579 87. S5.4-3. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461 70. S5.4-4. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:e463 654. S5.4-5. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266 81. S5.4-6. Funder JW, Carey RM, Mantero F, et al.


2008;93:3266 81. S5.4-6. Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889 916. S5.4-7. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associ- ated with resistant hypertension. Hypertension. 2011;58:811 7. S5.4-8. Kump K, Whalen C, Tishler PV, et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J. Respir Crit Care Med. 1994;150:735 41. S5.4-9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540 5. S5.4-10. Grossman E, Messerli FH. Drug-induced hypertension: an unap- preciated cause of secondary hypertension. Am J Med. 2012;125: 14 22. S5.4-11. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2014;99:1915 42. S5.4-12. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2008;93:1526 40. S5.4-13. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommenda- tions of the European Society of Hypertension. J Hypertens. 2009;27:1719 42. S5.4-14. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sam- ple. Br Med J. 1976;2:554 6. S5.4-15. Hassan-Smith Z, Stewart PM. Inherited forms of mineralo- corticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011;18:177 85. S5.4-16. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933 51. 5.4.1. Drugs and Other Substances With Potential to Impair BP Control S5.4.1-1.


Drugs and Other Substances With Potential to Impair BP Control S5.4.1-1. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154 83. S5.4.1-2. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:14 22. S5.4.1-3. Ong SLH, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am. 2011;40: 393 407; ix. S5.4.1-4. Rossi GP, Seccia TM, Maniero C, et al. Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J Hypertens. 2011;29:2295 309. S5.4.1-5. Tachjian A, Maria V, Jahangir A. Use of herbal products and poten- tial interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55:515 25. S5.4.1-6. Grossman E, Messerli FH. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich). 2008;10:556 66. S5.4.1-7. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare profes- sionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517 84. S5.4.1-8. Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227 46. S5.4.1-9. Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of atten- tion-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007 22. S5.4.1-10. Newcomer JW. Metabolic considerations in the use of antipsy- chotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20 7. S5.4.1-11. Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3: e001106. S5.4.1-12.


Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3: e001106. S5.4.1-12. Mesas AE, Leon-Munoz LM, Rodriguez-Artalejo F, et al. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr. 2011;94:1113 26. S5.4.1-13. Liu Y, Yang M-S, Yuan J-Y. Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis. Int Urol Nephrol. 2013;45:885 92. S5.4.1-14. Penninga L, Penninga EI, Moller CH, et al. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;5:CD008817. S5.4.1-15. Xue W, Zhang Q, Xu Y, et al. Effects of tacrolimus and cyclo- sporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med J. 2014;127:2376 81. S5.4.1-16. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. 5.4.2. Primary Aldosteronism S5.4.2-1. Montori VM, Young WF Jr. Use of plasma aldosterone concentra- tion-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31:619 32; xi. S5.4.2-2. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266 81. S5.4.2-3. Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889 916. S5.4.2-4. Mulatero P, Stowasser M, Loh K-C, et al.


2016;101:1889 916. S5.4.2-4. Mulatero P, Stowasser M, Loh K-C, et al. Increased diagno- sis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045 50. S5.4.2-5. Hannemann A, Wallaschofski H. Prevalence of primary aldosteron- ism in patient's cohorts and in population-based studies'a review of the current literature. Horm Metab Res. 2012;44:157 62. S5.4.2-6. Rossi GP, Bernini G, Desideri G, et al. Renal damage in pri- mary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232 8. S5.4.2-7. Milliez P, Girerd X, Plouin P-F, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243 8. S5.4.2-8. Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826 33. S5.4.2-9. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62 9. S5.4.2-10. Fourkiotis V, Vonend O, Diederich S, et al. Effectiveness of eplere- none or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol. 2013;168:75 81. 5.4.3. Renal Artery Stenosis S5.4.3-1. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13 22. S5.4.3-2. Riaz IB, Husnain M, Riaz H, et al. Meta-analysis of revasculariza- tion versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol. 2014;114:1116 23. S5.4.3-3. Olin JW, Froehlich J, Gu X, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation. 2012;125:3182 90. S5.4.3-4. Lamawansa MD, Bell R, House AK. Short-term and long-term outcome following renovascular reconstruction. Cardiovasc Surg. 1995;3:50 5. S5.4.3-5. Trinquart L, Mounier-Vehier C, Sapoval M, et al.


1995;3:50 5. S5.4.3-5. Trinquart L, Mounier-Vehier C, Sapoval M, et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010;56:525 32. 5.4.4. Obstructive Sleep Apnea S5.4.4-1. Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effect of con- tinuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010;181:718 26. S5.4.4-2. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310:2407 15. S5.4.4-3. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hyper- tension: a randomized, controlled trial. J Hypertens. 2010;28: 2161 8. S5.4.4-4. Muxfeldt ES, Margallo V, Costa LMS, et al. Effects of continu- ous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resis- tant hypertension: a randomized controlled trial. Hypertension. Hypertension. 2015;65:736 42. S5.4.4-5. Pedrosa RP, Drager LF, de Paula LKG, et al. Effects of OSA treat- ment on BP in patients with resistant hypertension: a randomized trial. Chest. 2013;144:1487 94. S5.4.4-6. Parati G, Lombardi C, Hedner J, et al. Position paper on the man- agement of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30:633 46. S5.4.4-7. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046 53. S5.4.4-8. Marshall NS, Wong KKH, Liu PY, et al.


2005;365:1046 53. S5.4.4-8. Marshall NS, Wong KKH, Liu PY, et al. Sleep apnea as an indepen- dent risk factor for all-cause mortality: the Busselton Health Study. Sleep. 2008;31:1079 85. S5.4.4-9. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disor- dered breathing, sleep apnea, and hypertension in a large com- munity-based study. Sleep Heart Health Study. JAMA. 2000;283: 1829 36. S5.4.4-10. Peppard PE, Young T, Palta M, et al. Prospective study of the asso- ciation between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378 84. S5.4.4-11. Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307:2169 76. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e87 S5.4.4-12. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associ- ated with resistant hypertension. Hypertension. 2011;58:811 7. S5.4.4-13. Muxfeldt ES, Margallo VS, Guimaraes GM, et al. Prevalence and associated factors of obstructive sleep apnea in patients with resis- tant hypertension. Am J Hypertens. 2014;27:1069 78. S5.4.4-14. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919 31. 6. Nonpharmacological Interventions S6-1. Whelton PK, He J, Appel LJ, et al. Primary prevention of hyper- tension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288: 1882 8. S6-2. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153:186 208. S6-3. Whelton PK. Hypertension curriculum review: epidemiology and the prevention of hypertension. J Clin Hypertens (Greenwich). 2004;6:636 42. S6-4. Whelton PK, Appel LJ, Espeland MA, et al.


2004;6:636 42. S6-4. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839 46. S6-5. Whelton PK. The elusiveness of population-wide high blood pres- sure control. Annu Rev Public Health. 2015;36:109 30. S6.1-1. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153:186 208. S6.1-2. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP). BMJ. 2007;334:885 8. S6.1-3. Rodgers A, MacMahon S. Blood pressure and the global bur- den of cardiovascular disease. Clin Exp Hypertens. 1999;21: 543 52. S6.1-4. Qin X, Jackson R, Marshall R, et al. Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China. Eur J Cardiovasc Prev Rehabil. 2009;16:96 101. S6.1-5. Zulman DM, Vijan S, Omenn GS, et al. The relative merits of population-based and targeted prevention strategies. Milbank Q. 2008;86:557 80. 6.2. Nonpharmacological Interventions S6.2-1. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878 84. S6.2-2. Whelton PK, Kumanyika SK, Cook NR, et al. Efficacy of nonphar- macologic interventions in adults with high-normal blood pres- sure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr. 1997;65:652S 60S. S6.2-3. The effects of nonpharmacologic interventions on blood pres- sure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:1213 20. S6.2-4.


Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:1213 20. S6.2-4. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657 67. S6.2-5. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pres- sure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3 10. S6.2-6. Appel LJ, Champagne CM, Harsha DW, et al. Effects of com- prehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289: 2083 93. S6.2-7. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117 24. S6.2-8. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium con- sumption and death from cardiovascular causes. N Engl J Med. 2014;371:624 34. S6.2-9. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326. S6.2-10. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta- analysis of randomised trials. BMJ. 2013;346:f1325. S6.2-11. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, cat- echolamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1 15. S6.2-12. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839 46. S6.2-13.


Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839 46. S6.2-13. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical tri- als. JAMA. 1997;277:1624 32. S6.2-14. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003;17:471 80. S6.2-15. World Health Organization. Guideline: Potassium Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2012. S6.2-16. Whelton PK, He J. Health effects of sodium and potassium in humans. Curr Opin Lipidol. 2014;25:75 9. S6.2-17. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potas- sium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378. S6.2-18. Cornelissen VA, Smart NA. Exercise training for blood pres- sure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473. S6.2-19. Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise train- ing for blood pressure management: a systematic review and meta- analysis. Mayo Clin Proc. 2014;89:327 34. S6.2-20. Garcia-Hermoso A, Saavedra JM, Escalante Y. Effects of exercise on resting blood pressure in obese children: a meta-analysis of ran- domized controlled trials. Obes Rev. 2013;14:919 28. S6.2-21. Rossi AM, Moullec G, Lavoie KL, et al. The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example. Can J Cardiol. 2013;29:622 7. S6.2-22. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493 503. S6.2-23. Xin X, He J, Frontini MG, et al.


2002;136:493 503. S6.2-23. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112 7. S6.2-24. Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduc- tion in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108 20. S6.2-25. Stewart SH, Latham PK, Miller PM, et al. Blood pressure reduc- tion during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008;103:1622 8. S6.2-26. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interven- tions to reduce raised blood pressure: a systematic review of ran- domized controlled trials. J Hypertens. 2006;24:215 33. S6.2-27. Wallace P, Cutler S, Haines A. Randomised controlled trial of gen- eral practitioner intervention in patients with excessive alcohol con- sumption. BMJ. 1988;297:663 8. S6.2-28. Lang T, Nicaud V, Darne B, et al. Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health. 1995;49:610 6. S6.2-29. National Institute on Alcohol Abuse and Alcoholism (NIAAA). What Is A Standard Drink? Available at: https://www.niaaa.nih. gov/alcohol-health/overview-alcohol-consumption/what-standard- drink. Accessed August 16, 2017. S6.2-30. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126 35. S6.2-31. Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training for blood pressure management: a systematic review and meta-anal- ysis to optimize benefit. Hypertens Res. 2016;39:88 94. S6.2-32. Khalesi S, Sun J, Buys N, et al. Effect of probiotics on blood pres- sure: a systematic review and meta-analysis of randomized, con- trolled trials. Hypertension.


Effect of probiotics on blood pres- sure: a systematic review and meta-analysis of randomized, con- trolled trials. Hypertension. 2014;64:897 903. S6.2-33. Dong J-Y, Szeto IMY, Makinen K, et al. Effect of probiotic fer- mented milk on blood pressure: a meta-analysis of randomised con- trolled trials. Br J Nutr. 2013;110:1188 94. S6.2-34. Cicero AFG, Gerocarni B, Laghi L, et al. Blood pressure lower- ing effect of lactotripeptides assumed as functional foods: a meta- analysis of current available clinical trials. J Hum Hypertens. 2011;25:425 36. S6.2-35. Rebholz CM, Friedman EE, Powers LJ, et al. Dietary protein intake and blood pressure: a meta-analysis of randomized controlled trials. Am J Epidemiol. 2012;176(suppl 7):S27 43. S6.2-36. Tielemans SMaJ,Altorf-van der Kuil W, Engberink MF, et al. Intake of total protein, plant protein and animal protein in relation to blood pressure: a meta-analysis of observational and intervention studies. J Hum Hypertens. 2013;27:564 71. S6.2-37. Dong J-Y, Zhang Z-L, Wang P-Y, et al. Effects of high-protein diets on body weight, glycaemic control, blood lipids and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. Br J Nutr. 2013;110:781 9. S6.2-38. Whelton SP, Hyre AD, Pedersen B, et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens. 2005;23:475 81. S6.2-39. Streppel MT, Arends LR, van't Veer P, et al. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165:150 6. S6.2-40. Rodriguez-Leyva D, Weighell W, Edel AL, et al. Potent antihy- pertensive action of dietary flaxseed in hypertensive patients. Hypertension. 2013;62:1081 9. S6.2-41. Campbell F, Dickinson HO, Critchley JA, et al. A systematic review of fish-oil supplements for the prevention and treatment of hyperten- sion. Eur J Prev Cardiol. 2013;20:107 20. S6.2-42. van Mierlo L a J, Arends LR, Streppel MT, et al.


van Mierlo L a J, Arends LR, Streppel MT, et al. Blood pressure response to calcium supplementation: a meta-analysis of random- ized controlled trials. J Hum Hypertens. 2006;20:571 80. S6.2-43. Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplemen- tation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015;6:CD010037. S6.2-44. Kass L, Weekes J, Carpenter L. Effect of magnesium supple- mentation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66:411 8. S6.2-45. Zhang X, Li Y, Del Gobbo LC, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of ran- domized double-blind placebo-controlled trials. Hypertension. 2016;68:324 33. S6.2-46. Bazzano LA, Hu T, Reynolds K, et al. Effects of low-carbo- hydrate and low-fat diets: a randomized trial. Ann Intern Med. 2014;161:309 18. S6.2-47. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohy- drate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:285 93. S6.2-48. Yokoyama Y, Nishimura K, Barnard ND, et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med. 2014;174:577 87. S6.2-49. Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al. Meta- analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med. 2011;124:841 51. S6.2-50. Rossi GP, Seccia TM, Maniero C, et al. Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J Hypertens. 2011;29:2295 309. S6.2-51. Nagele E, Jeitler K, Horvath K, et al. Clinical effectiveness of stress- reduction techniques in patients with hypertension: systematic review and meta-analysis. J Hypertens. 2014;32:1936 44. S6.2-52. Rohner A, Ried K, Sobenin IA, et al. A systematic review and meta- analysis on the effects of garlic preparations on blood pressure in individuals with hypertension. Am J Hypertens. 2015;28:414 23. S6.2-53.


A systematic review and meta- analysis on the effects of garlic preparations on blood pressure in individuals with hypertension. Am J Hypertens. 2015;28:414 23. S6.2-53. Egan BM, Laken MA, Donovan JL, et al. Does dark chocolate have a role in the prevention and management of hypertension? Commentary on the evidence. Hypertension. 2010;55:1289 95. S6.2-54. Ried K, Sullivan T, Fakler P, et al. Does chocolate reduce blood pressure? A meta-analysis. BMC Med. 2010;8:39. S6.2-55. Liu G, Mi X-N, Zheng X-X, et al. Effects of tea intake on blood pressure: a meta-analysis of randomised controlled trials. Br J Nutr. 2014;112:1043 54. S6.2-56. Steffen M, Kuhle C, Hensrud D, et al. The effect of coffee consump- tion on blood pressure and the development of hypertension: a sys- tematic review and meta-analysis. J Hypertens. 2012;30:2245 54. S6.2-57. Wang J, Xiong X, Liu W.Yoga for essential hypertension: a system- atic review. PLoS ONE. 2013;8:e76357. S6.2-58. Dickinson H, Campbell F, Beyer F, et al. Relaxation therapies for the management of primary hypertension in adults: a Cochrane review. J Hum Hypertens. 2008;22:809 20. S6.2-59. Lee MS, Pittler MH, Guo R, et al. Qigong for hypertension: a systematic review of randomized clinical trials. J Hypertens. 2007;25:1525 32. S6.2-60. Yeh GY, Wang C, Wayne PM, et al. The effect of tai chi exercise on blood pressure: a systematic review. Prev Cardiol. 2008;11:82 9. S6.2-61. Canter PH, Ernst E. Insufficient evidence to conclude whether or not transcendental meditation decreases blood pressure: results of a systematic review of randomized clinical trials. J Hypertens. 2004;22:2049 54. S6.2-62. Whelton PK, He J, Appel LJ, et al. Primary prevention of hyperten- sion: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882 8. S6.2-63. Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease.


Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med. 2013;369:676 7. S6.2-64. Look AHEAD Research Group; Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145 54. S6.2-65. Aucott L, Rothnie H, McIntyre L, et al. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension. 2009;54:756 62. S6.2-66. Straznicky N, Grassi G, Esler M, et al. European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality? J Hypertens. 2010;28: 637 43. S6.2-67. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl 2):S102 38. S6.2-68. Ryan DH. The pharmacological and surgical management of adults with obesity. J Fam Pract. 2014;63:S21 6. S6.2-69. Chang S-H, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003 2012. JAMA Surg. 2014;149:275 87. S6.2-70. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999;159:285 93. S6.2-71. Filippini T, Violi F, D'Amico R, et al. The effect of potassium sup- plementation on blood pressure in hypertensive subjects: a system- atic review and meta-analysis. Int J Cardiol. 2017;230:127 35. S6.2-72. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH How Do I Make the DASH? Available at: https://www.nhlbi.nih.gov/health/resources/heart/ hbp-dash-how-to. Accessed September 18, 2017. S6.2-73. Top 10 DASH Diet Tips.Available at: http://dashdiet.org/dash_diet_ tips.asp. Accessed September 18, 2017. S6.2-74.


Top 10 DASH Diet Tips.Available at: http://dashdiet.org/dash_diet_ tips.asp. Accessed September 18, 2017. S6.2-74. van Bommel E, Cleophas T. Potassium treatment for hypertension in patients with high salt intake: a meta-analysis. Int J Clin Pharmacol Ther. 2012;50:478 82. S6.2-75. He J, Wofford MR, Reynolds K, et al. Effect of dietary protein supplementation on blood pressure. Circulation. 2011;124:589 95. S6.2-76. Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation. 2014;129: 981 9. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e89 S6.2-77. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Orevention (TOHP). BMJ. 2007;334:885 8. S6.2-78. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475 81. S6.2-79. Huggins CE, Margerison C, Worsley A, et al. Influence of dietary modifications on the blood pressure response to antihypertensive medication. Br J Nutr. 2011;105:248 55. S6.2-80. He FJ, Fan S, Macgregor GA, et al. Plasma sodium and blood pressure in individuals on haemodialysis. J Hum Hypertens. 2013;27:85 9. S6.2-81. Whelton PK. Sodium, potassium, blood pressure, and cardiovascu- lar disease in humans. Curr Hypertens Rep. 2014;16:465. S6.2-82. Weinberger MH, Miller JZ, Luft FC, et al. Definitions and char- acteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8:II127 II34. S6.2-83. Mattes RD, Donnelly D. Relative contributions of dietary sodium sources. J Am Coll Nutr. 1991;10:383 93. S6.2-84. Anderson CAM, Appel LJ, Okuda N, et al. Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc. 2010;110:736 45. S6.2-85.


Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc. 2010;110:736 45. S6.2-85. Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pres- sure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880 9. S6.2-86. Cobb LK, Appel LJ, Anderson CAM. Strategies to reduce dietary sodium intake. Curr Treat Options Cardiovasc Med. 2012;14:425 34. S6.2-87. McGuire S; Institute of Medicine. 2010. Strategies to Reduce Sodium Intake in the United States. Washington, DC: The National Academies Press. Adv Nutr; 2010. 49 50. S6.2-88. He J, Tell GS, TangYC, et al. Effect of migration on blood pressure: the Yi People Study. Epidemiology. 1991;2:88 97. S6.2-89. Stamler J. The INTERSALT Study: background, methods, find- ings, and implications. Am J Clin Nutr. 1997;65:626S 42S. S6.2-90. Zhang Z, Cogswell ME, Gillespie C, et al. Association between usual sodium and potassium intake and blood pressure and hyper- tension among U.S. adults: NHANES 2005 2010. PLoS ONE. 2013;8:e75289. S6.2-91. Mente A, O'Donnell MJ, Rangarajan S, et al. Association of uri- nary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371:601 11. S6.2-92. Kieneker LM, Gansevoort RT, Mukamal KJ, et al. Urinary potas- sium excretion and risk of developing hypertension: the preven- tion of renal and vascular end-stage disease study. Hypertension. 2014;64:769 76. S6.2-93. Bazzano LA, He J, Ogden LG, et al. Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I epidemiologic follow-up study. Stroke. 2001;32:1473 80. S6.2-94. Ascherio A, Rimm EB, Hernan MA, et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation. 1998;98:1198 204. S6.2-95.


Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation. 1998;98:1198 204. S6.2-95. Seth A, Mossavar-RahmaniY, Kamensky V, et al. Potassium intake and risk of stroke in women with hypertension and nonhyperten- sion in the Women's Health Initiative. Stroke. 2014;45:2874 80. S6.2-96. D'Elia L, Barba G, Cappuccio FP, et al. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57:1210 9. S6.2-97. Bazzano LA, He J, Ogden LG, et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr. 2002;76:93 9. S6.2-98. Gu D, Zhao Q, Chen J, et al. Reproducibility of blood pressure responses to dietary sodium and potassium interventions: the GenSalt study. Hypertension. 2013;62:499 505. S6.2-99. Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med. 2009;169:32 40. S6.2-100. Whelton PK, Buring J, Borhani NO, et al. The effect of potas- sium supplementation in persons with a high-normal blood pres- sure. Results from phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol. 1995;5:85 95. S6.2-101. Dietary Guidelines Advisory Committee. Dietary Guidelines for Americans, 2015 2020. Washington, DC: Department of Health and Human Services (U.S.), Department of Agriculture (U.S); 2015. S6.2-102. Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC: The National Academies Press; 2005. S6.2-103. Cornelissen VA, Arnout J, Holvoet P, et al. Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age. J Hypertens. 2009;27:753 62. S6.2-104.


Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age. J Hypertens. 2009;27:753 62. S6.2-104. Klatsky AL, Gunderson E. Alcohol and hypertension: a review. J Am Soc Hypertens. 2008;2:307 17. S6.2-105. National Institute on Alcohol Abuse and Alcoholism (NIAAA). A Pocket Guide for Alcohol Screening and Brief Intervention. 2005; NIAAA: Rockville, MD. Available at: https://pubs.niaaa.nih.gov/ publications/practitioner/pocketguide/pocket_guide.htm. Accessed September 18, 2017. S6.2-106. Cushman WC, Cutler JA, Hanna E, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998;158:1197 207. S6.2-107. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523 8. S6.2-108. Mukamal KJ. Understanding the mechanisms that link alcohol and lower risk of coronary heart disease. Clin Chem. 2012;58:664 6. S6.2-109. Klatsky AL. Alcohol and cardiovascular mortality: common sense and scientific truth. J Am Coll Cardiol. 2010;55:1336 8. S6.2-110. Mukamal KJ, Chen CM, Rao SR, et al. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol. 2010;55:1328 5. 7. Patient Evaluation 7.1. Laboratory Tests and Other Diagnostic Procedures S7.1-1. Chang AR, Sang Y, Leddy J, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181 8. 7.2. Cardiovascular Target Organ Damage S7.2-1. Persu A, De Plaen J-F. Recent insights in the development of organ damage caused by hypertension. Acta Cardiol. 2004;59:369 81. S7.2-2. Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014;311:490 7. S7.2-3. Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149:91 9.


Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149:91 9. S7.2-4. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclero- sis: the International Childhood Cardiovascular Cohort Consortium. Circulation. 2013;128:217 24. S7.2-5. Santos M, Shah AM. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep. 2014;16:428. S7.2-6. Devereux RB, Roman MJ. Left ventricular hypertrophy in hyper- tension: stimuli, patterns, and consequences. Hypertens Res. 1999;22:1 9. S7.2-7. Gidding SS, Liu K, Colangelo LA, et al. Longitudinal determinants of left ventricular mass and geometry: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Circ Cardiovasc Imaging. 2013;6:769 75. S7.2-8. Fox ER, Musani SK, Samdarshi TE, et al. Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. J Am Heart Assoc. 2015;4:e001224. S7.2-9. Lieb W, Xanthakis V, Sullivan LM, et al. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study. Circulation. 2009;119:3085 92. S7.2-10. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ven- tricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698 706. S7.2-11. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084 91. S7.2-12. Norman JE Jr, Levy D. Improved electrocardiographic detec- tion of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol. 1995;26: 1022 9. S7.2-13. da Costa W, Riera ARP, Costa F de A, et al.


da Costa W, Riera ARP, Costa F de A, et al. Correlation of elec- trocardiographic left ventricular hypertrophy criteria with left ventricular mass by echocardiogram in obese hypertensive patients. J Electrocardiol. 2008;41:724 9. S7.2-14. Bacharova L, Schocken D, Estes EH, et al. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev. 2014;10:257 61. S7.2-15. Bang CN, Devereux RB, Okin PM. Regression of electrocardio- graphic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hyper- tensive patients independent of blood pressure reduction a LIFE review. J Electrocardiol. 2014;47:630 5. S7.2-16. Pewsner D, Juni P, Egger M, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711. S7.2-17. Rautaharju PM, Soliman EZ. Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal. J Electrocardiol. 2014;47:649 54. S7.2-18. Armstrong AC, Gidding S, Gjesdal O, et al. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. J Am Coll Cardiol Img. 2012;5:837 48. S7.2-19. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guide- line for assessment of cardiovascular risk in asymptomatic adults: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584 636. S7.2-20. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350 6. S7.2-21. Armstrong AC, Jacobs DR Jr, Gidding SS, et al. Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol. 2014;172:350 5. S7.2-22. Okwuosa TM, Soliman EZ, Lopez F, et al. Left ventricular hypertro- phy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J. 2015;169:155 61.


Left ventricular hypertro- phy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J. 2015;169:155 61. S7.2-23. Zalawadiya SK, Gunasekaran PC, Bavishi CP, et al. Left ventricular hypertrophy and risk reclassification for coronary events in multi- ethnic adults. Eur J Prev Cardiol. 2015;22:673 9. 8. Treatment of High BP 8.1. Pharmacological Treatment 8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk S8.1.1-1. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466 72. S8.1.1-2. Ozyilmaz A, Bakker SJL, de Zeeuw D, et al. Screening for albu- minuria with subsequent screening for hypertension and hypercho- lesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrol Dial Transplant. 2013;28: 2805 15. S8.1.1-3. Peters SAE, Huxley RR, Woodward M. Comparison of the sex- specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke. 2013;44:2394 401. S8.1.1-4. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43: 77 95. S8.1.1-5. Lawes CMM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355 68. S8.1.1-6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S8.1.1-7. Takashima N, OhkuboT, Miura K, et al. Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens. 2012;30:2299 306. S8.1.1-8.


Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens. 2012;30:2299 306. S8.1.1-8. Murakami Y. Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions. J Epidemiol. 2014;24:96 101. S8.1.1-9. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pres- sure lowering on cardiovascular outcomes in different cardiovascu- lar risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83 90. S8.1.1-10. Sundstrom J, Arima H, Woodward M, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-low- ering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591 8. S8.1.1-11. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospec- tively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410 9. S8.1.1-12. Wang J-G, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular out- come. Hypertension. 2005;45:907 13. S8.1.1-13. Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669 80. S8.1.1-14. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regi- mens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121 3. S8.1.1-15. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30:1128 35. S8.1.1-16. Czernichow S, Ninomiya T, Huxley R, et al.


2009;30:1128 35. S8.1.1-16. Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pres- sure lowering on cardiovascular outcomes in normal weight, over- weight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010;55:1193 8. S8.1.1-17. Heerspink HJL, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31:2888 96. S8.1.1-18. Ninomiya T, Zoungas S, Neal B, et al. Efficacy and safety of rou- tine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens. 2010;28:1141 9. S8.1.1-19. Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine- based therapy among older and younger patients in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens. 2011;29:583 91. S8.1.1-20. Ninomiya T, PerkovicV, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ. 2013;347:f5680. S8.1.1-21. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in com- bination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74 83. S8.1.1-22. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539 43. S8.1.1-23. van der Leeuw J, Visseren FLJ, Woodward M, et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results fromActioninDiabetesandVascularDisease:PreteraxandDiamicron MR Controlled Evaluation. Hypertension. 2015;65:115 21. 8.1.2.


Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results fromActioninDiabetesandVascularDisease:PreteraxandDiamicron MR Controlled Evaluation. Hypertension. 2015;65:115 21. 8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension S8.1.2-1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e91 S8.1.2-2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S8.1.2-3. Sundstrom J, Arima H, Woodward M, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-low- ering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591 8. S8.1.2-4. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S8.1.2-5. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-anal- ysis. Ann Intern Med. 2015;162:184 91. S8.1.2-6. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913 22. S8.1.2-7. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S8.1.2-8. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16.


A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S8.1.2-9. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4 16. S8.1.2-10. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S8.1.2-11. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pres- sure lowering on cardiovascular outcomes in different cardiovascu- lar risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83 90. S8.1.2-12. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the deci- sion to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1753 9. S8.1.2-13. Kassai B, Boissel J-P, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag. 2005;1:163 9. S8.1.2-13a. ACC/AHA Pooled Cohort Equations. Available at: (http://tools.acc. org/ASCVD-Risk-Estimator/. Accessed November 3, 2017. S8.1.2-14. Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk fac- tors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627. S8.1.2-15. Baker S, Priest P, Jackson R. Using thresholds based on risk of car- diovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ. 2000;320:680 5. S8.1.2-16. Gaziano TA, Steyn K, Cohen DJ, et al. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569 76. S8.1.2-17.


Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569 76. S8.1.2-17. Eddy DM, Adler J, Patterson B, et al. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med. 2011;154:627 34. S8.1.2-18. Marchant I, Nony P, Cucherat M, et al. The global risk approach should be better applied in French hypertensive patients: a com- parison between simulation and observation studies. PLoS ONE. 2011;6:e17508. S8.1.2-19. Cadilhac DA, Carter R, Thrift AG, et al. Organized blood pressure control programs to prevent stroke in Australia: would they be cost- effective? Stroke. 2012;43:1370 5. S8.1.2-20. Cobiac LJ, Magnus A, Barendregt JJ, et al. Improving the cost- effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12:398. S8.1.2-21. Cobiac LJ, Magnus A, Lim S, et al. Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS ONE. 2012;7:e41842. S8.1.2-22. Karmali KN, Lloyd-Jones DM. Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension. 2017;69:e2 9. S8.1.2-23. Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69:2446 56. S8.1.2-24. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128:2309 17. S8.1.2-25. van der Leeuw J, Ridker PM, van der Graaf Y, et al. Personalized cardiovascular disease prevention by applying individualized pre- diction of treatment effects. Eur Heart J. 2014;35:837 43. S8.1.2-26. Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle- income countries. J Hypertens. 2007;25:1578 82. S8.1.2-27.


World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle- income countries. J Hypertens. 2007;25:1578 82. S8.1.2-27. van Dis I, Geleijnse JM, Verschuren WMM, et al. Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. Neth Heart J. 2012;20:320 5. S8.1.2-28. Nelson MR, Doust JA. Primary prevention of cardiovascular dis- ease: new guidelines, technologies and therapies. Med J Aust. 2013;198:606 10. S8.1.2-29. JBS3 Board. Joint British Societies' consensus recommenda- tions for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(suppl 2):ii1 67. S8.1.2-30. World Health Organization. Prevention of Cardiovascular Disease. Guidelines for Assessment and Management of Cardiovascular Risk. Geneva, Switzerland: World Health Organization; 2007. S8.1.2-31. Anderson JL, Heidenreich PA, Barnett PG, et al.ACC/AHA statement on cost/value methodology in clinical practice guidelines and perfor- mance measures: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S8.1.2-32. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60. S8.1.2-33. Sheridan SL, Viera AJ, Krantz MJ, et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170:230 9. S8.1.2-34. Viera AJ, Sheridan SL. Global risk of coronary heart disease: assessment and application. Am Fam Physician. 2010;82:265 74. S8.1.2-35. Sheridan SL, Draeger LB, Pignone MP, et al. A randomized trial of an intervention to improve use and adherence to effective coro- nary heart disease prevention strategies. BMC Health Serv Res. 2011;11:331. S8.1.2-36. Brett T, Arnold-Reed D, Phan C, et al.


2011;11:331. S8.1.2-36. Brett T, Arnold-Reed D, Phan C, et al. The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute car- diovascular risk reduction. Br J Gen Pract. 2012;62:e22 8. S8.1.2-37. Sekaran NK, Sussman JB, Xu A, et al. Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescrib- ing: a true experiment using clinical vignettes. BMC Cardiovasc Disord. 2013;13:90. S8.1.2-38. Sheridan SL, Draeger LB, Pignone MP, et al. The effect of a deci- sion aid intervention on decision making about coronary heart dis- ease risk reduction: secondary analyses of a randomized trial. BMC Med Inform Decis Mak. 2014;14:14. S8.1.2-39. Jansen J, Bonner C, McKinn S, et al. General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ Open. 2014;4:e004812. S8.1.2-40. Vagholkar S, Zwar N, Jayasinghe UW, et al. Influence of cardiovas- cular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial. Am Heart J. 2014;167:28 35. S8.1.2-41. Rafter N, Connor J, Hall J, et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. N Z Med J. 2005;118:U1676. S8.1.2-42. Yong TY, Phillipov G, Phillips PJ. Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. Med J Aust. 2007;186:622 4. S8.1.2-43. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular dis- ease risk management in Australian general practice. Med J Aust. 2009;191:324 9. S8.1.2-44. Frikke-Schmidt R, Tybj rg-Hansen A, Schnohr P, et al. Common clinical practice versus new PRIM score in predicting coronary heart disease risk. Atherosclerosis. 2010;213:532 8. S8.1.2-45. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk percep- tion and evidence practice gaps in Australian general practice (the AusHEART study). Med J Aust. 2010;192:254 9. S8.1.2-46.


Cardiovascular risk percep- tion and evidence practice gaps in Australian general practice (the AusHEART study). Med J Aust. 2010;192:254 9. S8.1.2-46. Shillinglaw B, Viera AJ, Edwards T, et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res. 2012;12:20. S8.1.2-47. Game FL, Bartlett WA, Bayly GR, et al. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes Obes Metab. 2001;3:279 86. S8.1.2-48. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham pre- diction rule is not valid in a European population of treated hyper- tensive patients. J Hypertens. 2002;20:1973 80. S8.1.2-49. Menotti A, Puddu PE, Lanti M. The estimate of cardiovascular risk. Theory, tools and problems. Ann Ital Med Int. 2002;17:81 94. S8.1.2-50. de Visser CL, Bilo HJG, Thomsen TF, et al. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med. 2003;253:553 62. S8.1.2-51. Persson M, Carlberg B, Weinehall L, et al. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens. 2003;21:1089 95. S8.1.2-52. Doust J, Sanders S, Shaw J, et al. Prioritising CVD prevention therapy absolute risk versus individual risk factors. Aust Fam Physician. 2012;41:805 9. S8.1.2-53. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardio- vascular disease risk calculators. Circulation. 2013;127:1948 56. S8.1.2-54. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart. 2002;88:222 8. S8.1.2-55. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group.


The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1 8. S8.1.2-56. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S8.1.2-57. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce athero- sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 45. S8.1.2-58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pres- sure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305 14. S8.1.2-59. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.2-60. Julius S, Kaciroti N, Egan BM, et al. TROPHY study: outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2:39 43. S8.1.2-61. Luders S, Schrader J, Berger J, et al. The PHARAO study: pre- vention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487 96. S8.1.2-62. Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, et al. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER Prevention Randomized Clinical Trial. J Am Heart Assoc. 2016;5:e004248. S8.1.2-63. Lonn EM, Bosch J, Lopez-Jaramillo P, et al.


2016;5:e004248. S8.1.2-63. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lower- ing in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009 20. 8.1.3. Follow-Up After Initial BP Evaluation S8.1.3-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.1.3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. S8.1.3-3. CarsonAP, Howard G, Burke GL, et al. Ethnic differences in hyper- tension incidence among middle-aged and older adults: the Multi- Ethnic study of Atherosclerosis. Hypertension. 2011;57:1101 7. 8.1.4. General Principles of Drug Therapy S8.1.4-1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547 59. S8.1.4-2. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204 13. S8.1.4-3. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892 903. S8.1.4-4. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967;202:1028 34. S8.1.4-5. Five-year findings of the hypertension detection and follow-up pro- gram. I. Reduction in mortality of persons with high blood pres- sure, including mild hypertension. Hypertension Detection and Follow-upProgramCooperativeGroup.JAMA.1979;242:2562 71. S8.1.4-6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.


Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255 64. S8.1.4-7. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306:2588 93. S8.1.4-8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S8.1.4-9. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S8.1.4-10. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4 16. S8.1.4-11. Fretheim A, Odgaard-Jensen J, Brors O, et al. Comparative effec- tiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med. 2012;10:33. S8.1.4-12. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393 404. S8.1.4-13. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13:146 54. S8.1.4-14. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group. N Engl J Med. 2010;362:1575 85. S8.1.4-15. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee.


Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. 8.1.5. BP Goal for Patients With Hypertension S8.1.5-1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S8.1.5-2. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S8.1.5-3. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642 53. S8.1.5-4. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pres- sure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;30:707 19.e8. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e93 S8.1.5-5. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S8.1.5-6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.5-7. Lawes CMM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355 68. S8.1.5-8. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lower- ing in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009 20. S8.1.5-9. Neaton JD, Grimm RH Jr, Prineas RJ, et al.


S8.1.5-9. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713 24. S8.1.5-10. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S8.1.5-11. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. S8.1.5-12. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S8.1.5-13. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S8.1.5-14. Cushman WC, Evans GW, Byington RP, et al. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med. 2010;362:1575 85. S8.1.5-15. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S8.1.5-16. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507 15. S8.1.5-17. PerkovicV, RodgersA. Redefining blood-pressure targets SPRINT starts the marathon. N Engl J Med. 2015;373:2175 8. S8.1.5-18. Lawes CMM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707 16. S8.1.5-19. Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014;311:490 7. S8.1.5-20.


Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014;311:490 7. S8.1.5-20. Ference BA, Julius S, Mahajan N, et al. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63:1182 8. 8.1.6. Choice of Initial Medication S8.1.6-1. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S8.1.6-2. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes asso- ciated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534 44. S8.1.6-3. ALLHAT Officers and Coordinators for theALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or cal- cium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981 97. S8.1.6-4. Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA. 1997;277:728 34. S8.1.6-5. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and preva- lence of heart failure in elderly persons, 1994 2003. Arch Intern Med. 2008;168:418 24. S8.1.6-6. Bleumink GS, Knetsch AM, Sturkenboom MCJM, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25:1614 9. S8.1.6-7. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699 703. S8.1.6-8. Ogedegbe G, Shah NR, Phillips C, et al.


2004;27:699 703. S8.1.6-8. Ogedegbe G, Shah NR, Phillips C, et al. Comparative effective- ness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol. 2015;66:1224 33. S8.1.6-9. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006;48:374 84. S8.1.6-10. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha- blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239 46. S8.1.6-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S8.1.6-12. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure- lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-over- view and meta-analyses. J Hypertens. 2015;33:1321 41. S8.1.6-13. ZhangY, Sun N, Jiang X, et al. Comparative efficacy of -blockers on mortality and cardiovascular outcomes in patients with hyper- tension: a systematic review and network meta-analysis. J Am Soc. Hypertens. 2017;11:394 401. S8.1.6-14. Larochelle P, Tobe SW, Lacourciere Y. -Blockers in hyperten- sion: studies and meta-analyses over the years. Can J Cardiol. 2014;30:S16 22. 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy S8.1.6.1-1. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S8.1.6.1-2. Law MR, Wald NJ, Morris JK, et al.


2003;42:1206 52. S8.1.6.1-2. Law MR, Wald NJ, Morris JK, et al. Value of low dose combina- tion treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. S8.1.6.1-3. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose com- binations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713 9. S8.1.6.1-4. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417 28. S8.1.6.1-5. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta- analysis. Ann Intern Med. 2015;162:184 91. S8.1.6.1-6. Luders S, Schrader J, Berger J, et al. The PHARAO study: pre- vention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487 96. S8.1.6.1-7. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255 61. 8.2. Achieving BP Control in Individual Patients S8.2-1. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713 24. S8.2-2. Senn S. Individual response to treatment: is it a valid assumption? BMJ. 2004;329:966 8. 8.3. Follow-Up of BP During Antihypertensive Drug Therapy S8.3-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and ratio- nale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.3-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i.


Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. 8.3.1. Follow-Up After Initiating Antihypertensive Drug Therapy S8.3.1-1. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532 46. S8.3.1-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i 55i. S8.3.1-3. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pres- sure target, time to intensification, and time to follow-up in treat- ment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158. 8.3.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP S8.3.2-1. Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African Americans. Popul Health Manag. 2010;13:65 72. S8.3.2-2. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151:687 95. S8.3.2-3. Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pres- sure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171: 1173 80. S8.3.2-4. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299:2857 67. S8.3.2-5. Heisler M, Hofer TP, Schmittdiel JA, et al.


2008;299:2857 67. S8.3.2-5. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pres- sure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster random- ized, controlled pragmatic trial. Circulation. 2012;125:2863 72. S8.3.2-6. Margolis KL,Asche SE, BergdallAR, et al. Effect of home blood pres- sure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46 56. 9. Hypertension in Patients With Comorbidities S9-1. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506. S9-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guide- line for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128: e240 327. S9-3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S9-4. Gerhard-Herman MD, Gornik HL, Barrett C, et al.


2014;130:1749 67. S9-4. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ ACC guideline on the management of patients with lower extrem- ity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726 79. 9.1. Stable Ischemic Heart Disease S9.1-1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.1-2. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S9.1-3. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374 84. S9.1-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163 8. S9.1-5. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha- blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239 46. S9.1-6. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S9.1-7. Fox KM.


2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S9.1-7. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronaryArtery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782 8. S9.1-8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S9.1-9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc- tion after myocardial infarction. Results of the survival and ven- tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. S9.1-10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con- verting-enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 53. S9.1-11. Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of vera- pamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol. 1981;48:131 9. S9.1-12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757 64. S9.1-13. Freemantle N, Cleland J, Young P, et al.


1997;350:757 64. S9.1-13. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myo- cardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. S9.1-14. de Peuter OR, Lussana F, Peters RJG, et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284 94. S9.1-15. Bavry AA, Anderson RD, GongY, et al. Outcomes among hyperten- sive patients with concomitant peripheral and coronary artery dis- ease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48 53. S9.1-16. Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long- term follow-up of participants with peripheral arterial disease dur- ing ALLHAT. J Gen Intern Med. 2014;29:1475 83. S9.1-17. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyper- tension in patients with coronary artery disease: a scientific state- ment from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435 70. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e95 S9.1-18. Ekelund LG, Olsson AG, Oro L, et al. Effects of the cardiose- lective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests. Br Heart J. 1976;38:155 61. S9.1-19. Aronow WS, Turbow M, Van Camp S, et al. The effect of timolol vs placebo on angina pectoris. Circulation. 1980;61:66 9. S9.1-20. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506.


Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434 506. S9.1-21. Aronow WS, Frishman WH. Angina pectoris in the elderly. Aronow WS, Fleg JL, Rich MW. Tresch and Aronow's Cardiovascular Disease in the Elderly. 2013; CRC Press, Taylor & Francis Group: Boca Raton, FL:215 37. S9.1-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF second- ary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. S9.1-23. Carlberg B, Samuelsson O, Lindholm LH.Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684 9. S9.1-24. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S9.1-25. Fihn SD, Gardin JM,Abrams J, et al. 2012ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. 9.2. Heart Failure S9.2-1. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.2-2. Thomopoulos C, Parati G, Zanchetti A.


CMAJ. 2013;185:949 57. S9.2-2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S9.2-3. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S9.2-4. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2-5. Visser M, Langlois J, Guralnik JM, et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr. 1998;68:584 90. S9.2-6. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059 64. S9.2-7. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart. 2011;97:1304 11. S9.2-8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S9.2-9. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group.


A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S9.2-10. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. 9.2.1. Heart Failure With Reduced Ejection Fraction S9.2.1-1. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52 60. S9.2.1-2. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.1-3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.1-4. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of con- gestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631 9. S9.2.1-5. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S9.2.1-6. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart fail- ure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948 55. S9.2.1-7. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2.1-8.


2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S9.2.1-8. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349 54. S9.2.1-9. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212 6. S9.2.1-10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper- tension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. S9.2.1-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S9.2.1-12. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with pre- served and reduced left ventricular ejection fraction in the antihy- pertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259 67. S9.2.1-13. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2011;124:1811 8. S9.2.1-14. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137 61. 9.2.2. Heart Failure With Preserved Ejection Fraction S9.2.2-1.


2017;136:e137 61. 9.2.2. Heart Failure With Preserved Ejection Fraction S9.2.2-1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34 42. S9.2.2-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline forthemanagementofheartfailure:areportoftheAmericanCollege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S9.2.2-3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207 9. S9.2.2-4. vanVeldhuisen DJ, Cohen-SolalA, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150 8. S9.2.2-5. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejec- tion fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S9.2.2-6. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S9.2.2-7. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.2-8. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.2-9. Vasan RS, Larson MG, Benjamin EJ, et al.